Unicancer
Carine Bellera is a highly experienced Lead & Senior Biostatistician at the Institut Bergonié, focusing on clinical research and clinical epidemiology since April 2006. In addition to this role, Carine has been a Research Associate at INSERM since January 2009 and provides expertise in cancer clinical trials for various organizations, including Institut national du cancer and UNICANCER. Carine's contributions extend to grant reviewing and membership in scientific evaluation committees for national programs. With previous roles at McGill University and as a faculty member for the European Society for Medical Oncology, Carine brings a strong educational background, holding a Ph.D. in Biostatistics & Epidemiology from McGill University and an Habilitation à Diriger des Recherches from Université de Bordeaux.
This person is not in any teams
Unicancer
UNICANCER groups together the 20 French Comprehensive Cancer Centres (FCCCs) which are private, not-for-profit hospitals located across the French territory. FCCCs are dedicated to fighting cancer through a threefold mission of patient care, research and education. They contribute to the public hospital service in accordance with statutory fees, with no additional charge. UNICANCER is one of the largest cancer care and research organisations in Europe. Via its R&D department, it sponsors clinical trials to improve cancer patients’ care and access to innovation, particularly in areas neglected by the pharmaceutical industry. UNICANCER is accredited by the French Ministry of Health and is eligible for public grants. The French Comprehensive Cancer Centres in numbers: • 20 sites located throughout the French territory • 19,000 employees • >135,000 patients hospitalised each year • Approximately 500 active clinical trials • 17% of the patients treated are included in a clinical trial (vs an average of 8.5% of cancer patients in France) • 19 molecular biology platforms certified by the French National Cancer Institute • 7 integrated cancerology research sites (SIRIC) certified by the French NCI (out of 8) • 12 early-phase clinical trial Centres (CLIP²) certified by the French NCI (out of 16) • 5th for global publications in oncology • 32% of French publications in oncology (articles in which FCCCs have participated) UNICANCER sponsors • 76 ongoing clinical trials (2016) • Including 5400 patients (2016) • From 270 investigator sites (2015), • With 20% located in other European countries